Results 241 to 250 of about 47,434 (363)

In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation

Advanced Science, Volume 12, Issue 37, October 6, 2025.
In this review, the basic concepts of in situ vaccination are discussed, its advantages over conventional vaccines, and key historical milestones, from the first use of Coley's toxins to the most recent FDA‐approved in situ vaccine for bladder cancer.
Yiru Shi, Yuxuan Hou, Moustafa T. Mabrouk, Chengzhong Yu, Yannan Yang   +4 more
wiley   +1 more source

Liquid biopsy: a step forward in laboratory medicine

Advances in Laboratory Medicine
Díaz-Lagares Angel, Jiménez Wladimiro
doaj   +1 more source

Reliable on-treatment prognostication and target identification with a customized assay for circulating tumor DNA in patients with newly diagnosed pancreatic cancer. [PDF]

Sci Rep
Petersson A, Svensson M, Hau SO, Bergström R, Lindberg J, Mayrhofer M, Chattopadhyay S, Eberhard J, Heidenblad M, Leandersson K, Gisselsson D, Jirström K.   +11 more
europepmc   +1 more source

RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies in patients with metastatic colorectal cancer (mCRC) [PDF]

, 2019
Yu Sunakawa, Masato Nakamura, M. Ishizaki, M. Kataoka, Hironaga Satake, Masaki Kitazono, Hideyuki Yanagisawa, Yasuyuki Kawamoto, Hidekazu Kuramochi, Hisatugu Ohori, Michio Nakamura, Kosuke Takahashi, F. Maeda, Chihiro Komeno, Masahiro Takeuchi, Masashi Fujii, T. Yoshino, Wataru Ichikawa, Akihito Tsuji   +18 more
openalex   +1 more source

Re‐Innovation in Clinical Trial Designs Based on Precision Therapy

Cancer Innovation, Volume 4, Issue 5, October 2025.
This article, centered on precision therapy, argues that traditional disease‐centered clinical trials are flawed with prolonged cycles, insufficient early‐phase samples, and inflexible protocols, thus proposing the concept of “clinical trial re‐innovation.” It elaborates that this re‐innovation, driven by biomarker technology, multi‐arm multi‐stage ...
Shenglan Li, Jiachen Wang, Zhuang Kang, Xun Kang, Feng Chen, Wenbin Li   +5 more
wiley   +1 more source

Blood-Based Cell-Free DNA in Ophthalmic Oncology. [PDF]

Transl Vis Sci Technol
Francis JH, Abramson DH.
europepmc   +1 more source

Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions

, 2018
Young Kwang Chae, Michael S. Oh
openalex   +1 more source

The therapeutic value of cerebrospinal fluid ctDNA detection by next-generation sequencing for meningeal carcinomatosis: a case report [PDF]

, 2019
Xiaosu Guo, Junzhao Cui, Yue Zhao, Weixin Han, Yueli Zou, Ruiping Gao, Qing Li, Xiaoqing Li, Junying He, Hui Bu   +9 more
openalex   +1 more source

Research Advances of Extrachromosomal Circular DNA in Breast Cancer

Cancer Medicine, Volume 14, Issue 19, October 2025.
ABSTRACT Background This article presents an extensive review of the advancements in research concerning extrachromosomal circular DNA (ecDNA) within the context of breast cancer. As a distinct form of DNA, ecDNA is critically involved in the initiation, progression, diagnosis, and treatment of breast cancer.
Xiaodan Zhu, Yiyang Qian, Quan Tang, Jiahui Li, Yuqing Geng, Shixia Gong, Chunhui Jin   +6 more
wiley   +1 more source

Circulating tumor DNA predicts prognosis at different time points in patients with esophageal cancer: a systematic review and meta-analysis. [PDF]

Front Oncol
Wang M, Xiong C, Wang S, Qiu Y, Hou Z, Gao P.   +5 more
europepmc   +1 more source